CERO THERAPEUTICS HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $253.05K
- P/E (TTM)
- –
- Dividend yield
- 172833.33%
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2024 Ended Sep 30, 2024 | Oct 11, 2024 | After market close | – | – | – |
Press releases
Announcements Cero Therapeutics filed with the SEC
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
January 7. 2026 CERTAINT - 1 Trial Update
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED JANUARY 7, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE DATED OCTOBER 29, 2025
Listing notice · Other events · EX-99.1 to Form 8-K
INVESTOR PRESENTATION, DATED SEPTEMBER 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 5, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 17, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 11, 2025
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED JUNE 6, 2025
Unregistered share sale · Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF CERO THERAPEUTICS HOLDINGS, INC., DATED MAY 8, 2025
Other events · EX-99.1 to Form 8-K
INVESTOR PRESENTATION, DATED APRIL 2025.
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE OF CERO THERAPEUTICS HOLDINGS, INC., DATED APRIL 22, 2025
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
PRESS RELEASE (PRICING) DATED FEBRUARY 5, 2025
Material agreement · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JANUARY 6, 2025
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED DECEMBER 6, 2024
Executive or director change · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED NOVEMBER 15, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED OCTOBER 21, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED OCTOBER 2, 2024
Executive or director change · Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF CERO THERAPEUTICS HOLDINGS, INC., DATED SEPTEMBER 25, 2024
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
CONSOLIDATED FINANCIAL STATEMENTS OF CERO FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022
Other events · EX-99.1 to Form 8-K/A
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF THE COMPANY FOR THE YEAR ENDED DECEMBER 31, 2023
Other events · EX-99.2 to Form 8-K/A
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF CERO FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022
Other events · EX-99.3 to Form 8-K/A
INVESTOR PRESENTATION, DATED AUGUST 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
PROXY SUPPLEMENT, DATED JULY 3, 2023
Unregistered share sale · Other events · EX-99.1 to Form 8-K
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp.
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
The Next Era in Cell Therapy MAY 2023
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Intrinsic Medicine and Phoenix Biotech Acquisition Corp.
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
CORPORATE PRESENTATION Developing New Drugs for Gut-Brain Axis Disorders October 2022
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Other events · EX-99.1 to Form 8-K
Phoenix Biotech Acquisition Corp. Announces Pricing of $155,000,000 Initial Public Offering
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Phoenix Biotech Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K